Applied Viromics

Executive Summary

Applied Viromics is a privately held biotechnology company headquartered in Bellevue, Washington, focused on enabling early drug discovery and development through custom-designed recombinant viral vectors for efficient in vitro and in vivo gene delivery. Founded in 2017, the company leverages its expertise in virology and vector engineering to provide tailored solutions for gene therapy, vaccine development, and basic research. Its platform addresses critical needs in the rapidly growing gene therapy market, offering versatility in vector design for diverse applications. While financial details and specific pipelines are not publicly disclosed, the company's niche in custom viral vectors positions it as a potential enabler for both academic and commercial partners seeking optimized gene delivery tools. With the gene therapy field expanding, Applied Viromics could capture value by serving as a specialized contract development and manufacturing organization or by advancing its own proprietary vectors.

Upcoming Catalysts (preview)

• TBDPotential Series A funding round to scale operations60% success
• Q3 2026Strategic partnership or licensing deal with a larger biopharma50% success
• Q4 2026Publication of preclinical data demonstrating vector performance70% success